AR075369A1 - Comprimidos para terapia de combinacion para el tratamiento de infecciones virales. - Google Patents

Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.

Info

Publication number
AR075369A1
AR075369A1 ARP100100328A ARP100100328A AR075369A1 AR 075369 A1 AR075369 A1 AR 075369A1 AR P100100328 A ARP100100328 A AR P100100328A AR P100100328 A ARP100100328 A AR P100100328A AR 075369 A1 AR075369 A1 AR 075369A1
Authority
AR
Argentina
Prior art keywords
formula
compound
layer
compressed
treatment
Prior art date
Application number
ARP100100328A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR075369A1 publication Critical patent/AR075369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presentacion provee formas de dosificacion solidas (por ejemplo, comprimidos) que comprenden un compuesto de la formula (1), un compuesto de la formula (2), un compuesto de la formula (3) y una sal de la formula (4). Reivindicacion 1: Un comprimido que comprende una primera capa y una segunda capa en donde a) la primera capa comprende: un compuesto de la formula (1), un compuesto de la formula (2) y opcionalmente un portador farmacéuticamente aceptable; y b) la segunda capa comprende: un compuesto de la formula (3) una sal de la formula (4) y opcionalmente un portador farmacéuticamente aceptable. Reivindicacion 2: El comprimido de acuerdo con la reivindicacion 1, en donde la primera capa está en contacto con la segunda capa. Reivindicacion 4: El comprimido de acuerdo con cualquiera de las reivindicaciones 1-3, en donde la primera capa también comprende una pluralidad de partículas de sílice. Reivindicacion 6: El comprimido de acuerdo con cualquiera de las reivindicaciones 1-5 que comprende 150 mg +- 10% del compuesto de la formula (1); 150 mg +- 10% del compuesto de la formula (2); 200 mg +- 10% del compuesto de la formula (3); y 300 mg +- 10% del compuesto de la formula (4). Reivindicacion 16: El comprimido de acuerdo con cualquiera de las reivindicaciones 1-15 que se formula en una forma de dosificacion unitaria.
ARP100100328A 2009-02-06 2010-02-05 Comprimidos para terapia de combinacion para el tratamiento de infecciones virales. AR075369A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06

Publications (1)

Publication Number Publication Date
AR075369A1 true AR075369A1 (es) 2011-03-30

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100328A AR075369A1 (es) 2009-02-06 2010-02-05 Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.

Country Status (31)

Country Link
US (2) US20100285122A1 (es)
EP (1) EP2393485B1 (es)
JP (2) JP5611242B2 (es)
KR (2) KR101738325B1 (es)
CN (1) CN102307573B (es)
AP (1) AP3250A (es)
AR (1) AR075369A1 (es)
AU (1) AU2010210598B2 (es)
BR (1) BRPI1008664A2 (es)
CA (1) CA2750521A1 (es)
CL (1) CL2011001885A1 (es)
CY (1) CY1116852T1 (es)
DK (1) DK2393485T3 (es)
EA (2) EA021313B1 (es)
EC (1) ECSP11011307A (es)
ES (1) ES2548886T3 (es)
HK (1) HK1164737A1 (es)
HR (1) HRP20151009T1 (es)
HU (1) HUE025822T2 (es)
IL (1) IL214227A (es)
MX (1) MX2011008289A (es)
NZ (1) NZ594214A (es)
PE (1) PE20110994A1 (es)
PL (1) PL2393485T3 (es)
PT (1) PT2393485E (es)
SG (3) SG173544A1 (es)
SI (1) SI2393485T1 (es)
SM (1) SMT201500266B (es)
TW (1) TWI444367B (es)
UY (1) UY32424A (es)
WO (1) WO2010091197A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696171A1 (en) 2006-07-07 2020-08-19 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2603617T3 (es) * 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
KR101784647B1 (ko) * 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
KR101923103B1 (ko) 2010-11-19 2018-11-28 길리애드 사이언시즈, 인코포레이티드 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물
ES2744926T3 (es) * 2010-11-29 2020-02-26 Formac Pharmaceuticals N V Formulaciones comprimidas de sílices mesoporosas ordenadas
RS56667B1 (sr) * 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Kombinovane formulacije darunavira
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ， インコーポレイテッド 噴霧乾燥製剤
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
KR102527797B1 (ko) 2012-12-21 2023-05-03 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
SI4070787T1 (sl) 2015-06-30 2023-07-31 Gilead Sciences, Inc. Farmacevtske formulacije
TWI737647B (zh) 2015-11-09 2021-09-01 美商基利科學股份有限公司 用於治療人類免疫缺乏病毒之治療組合物
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EP4059923A1 (en) 2002-11-20 2022-09-21 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AU2006325404B2 (en) * 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
EP3696171A1 (en) 2006-07-07 2020-08-19 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2603617T3 (es) * 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica

Also Published As

Publication number Publication date
JP5911927B2 (ja) 2016-04-27
IL214227A (en) 2017-01-31
SG10201706215UA (en) 2017-08-30
CA2750521A1 (en) 2010-08-12
EA201190125A1 (ru) 2012-01-30
NZ594214A (en) 2013-05-31
TW201040142A (en) 2010-11-16
AU2010210598B2 (en) 2015-03-05
TWI444367B (zh) 2014-07-11
JP2012517432A (ja) 2012-08-02
EA021313B1 (ru) 2015-05-29
AP2011005857A0 (en) 2011-10-31
EP2393485A2 (en) 2011-12-14
EP2393485B1 (en) 2015-07-29
ECSP11011307A (es) 2011-10-31
HRP20151009T1 (hr) 2015-10-23
US20100285122A1 (en) 2010-11-11
PE20110994A1 (es) 2012-01-24
AP3250A (en) 2015-05-31
SI2393485T1 (sl) 2015-10-30
WO2010091197A2 (en) 2010-08-12
UY32424A (es) 2010-09-30
US20150150810A1 (en) 2015-06-04
CL2011001885A1 (es) 2012-05-25
EA201491658A1 (ru) 2015-05-29
DK2393485T3 (en) 2015-10-26
EA030123B1 (ru) 2018-06-29
IL214227A0 (en) 2011-09-27
ES2548886T3 (es) 2015-10-21
KR20160093100A (ko) 2016-08-05
BRPI1008664A2 (pt) 2016-03-08
PL2393485T3 (pl) 2015-12-31
SG173544A1 (en) 2011-09-29
KR101738325B1 (ko) 2017-05-19
CY1116852T1 (el) 2017-04-05
JP2014221845A (ja) 2014-11-27
CN102307573A (zh) 2012-01-04
JP5611242B2 (ja) 2014-10-22
PT2393485E (pt) 2015-10-23
AU2010210598A1 (en) 2011-08-25
SG2014007744A (en) 2014-05-29
SMT201500266B (it) 2016-01-08
HK1164737A1 (en) 2012-09-28
KR101645759B1 (ko) 2016-08-04
WO2010091197A3 (en) 2011-06-03
CN102307573B (zh) 2013-09-11
KR20110122729A (ko) 2011-11-10
MX2011008289A (es) 2011-09-15
HUE025822T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
PA8809601A1 (es) Combinación anti-retroviral
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
SMT201500317B (it) Forma di dosaggio farmaceutica per la somministrazione orale di un inibitore della famiglia di bcl-2
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP088490A (es) Forma farmacéutica oral que contiene como principios activos un inhibidor de la bomba de protones junto con ácido acetilsalicílico
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY29193A1 (es) Nuevas formulaciones de tabletas de liberación modificada para inhibidores de bomba de protón
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CL2011002643A1 (es) Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.
ECSP13012791A (es) Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
UY35209A (es) Compuestos tricíclicos
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
GT201400042A (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
FB Suspension of granting procedure